Syros Non Currrent Assets Other vs Other Stockholder Equity Analysis

SYRS Stock

USD 0.28 0.08 22.22%

Syros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syros Pharmaceuticals is a good investment. Please check the relationship between Syros Pharmaceuticals Non Currrent Assets Other and its Other Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Non Currrent Assets Other vs Other Stockholder Equity

Non Currrent Assets Other vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syros Pharmaceuticals Non Currrent Assets Other account and Other Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity is 0.81. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Syros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Syros Pharmaceuticals are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Non Currrent Assets Other i.e., Syros Pharmaceuticals' Non Currrent Assets Other and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Other Stockholder Equity

Most indicators from Syros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 86.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.

Syros Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross
Total Assets		0.81	0.91	0.44	0.81	0.85	0.9	-0.47	-0.83	0.56	0.84	0.89	0.75	0.81	0.88	0.97	0.03	0.69	0.55	-0.16	0.85	0.88	0.92	0.86	0.18	0.94
Other Current Liab	0.81		0.92	0.28	0.66	0.88	0.71	-0.12	-0.82	0.64	0.49	0.73	0.74	0.52	0.86	0.78	0.43	0.72	0.58	0.12	0.69	0.81	0.9	0.74	-0.25	0.76
Total Current Liabilities	0.91	0.92		0.18	0.8	0.9	0.87	-0.24	-0.91	0.72	0.68	0.87	0.8	0.74	0.91	0.86	0.19	0.72	0.66	-0.14	0.86	0.86	0.98	0.89	0.06	0.91
Total Stockholder Equity	0.44	0.28	0.18		-0.01	0.1	0.31	-0.13	0.08	-0.41	0.28	0.33	0.21	0.2	0.35	0.45	0.2	0.28	-0.43	0.53	-0.08	0.28	0.21	-0.06	0.07	0.33
Other Liab	0.81	0.66	0.8	-0.01		0.83	0.78	-0.53	-0.85	0.81	0.73	0.68	0.44	0.77	0.75	0.79	0.07	0.72	0.76	-0.43	0.91	0.74	0.79	0.91	0.09	0.75
Net Tangible Assets	0.85	0.88	0.9	0.1	0.83		0.73	-0.39	-0.93	0.77	0.66	0.72	0.66	0.65	0.76	0.85	0.15	0.74	0.79	-0.28	0.88	0.8	0.9	0.9	-0.2	0.77
Property Plant And Equipment Net	0.9	0.71	0.87	0.31	0.78	0.73		-0.16	-0.75	0.56	0.63	0.97	0.64	0.76	0.86	0.78	0.14	0.73	0.45	-0.09	0.8	0.73	0.83	0.81	0.36	0.97
Net Debt	-0.47	-0.12	-0.24	-0.13	-0.53	-0.39	-0.16		0.39	-0.26	-0.82	-0.11	-0.19	-0.59	-0.2	-0.62	0.52	-0.16	-0.41	0.67	-0.51	-0.41	-0.33	-0.46	-0.08	-0.21
Retained Earnings	-0.83	-0.82	-0.91	0.08	-0.85	-0.93	-0.75	0.39		-0.89	-0.7	-0.75	-0.76	-0.65	-0.76	-0.81	0.01	-0.55	-0.9	0.37	-0.96	-0.86	-0.92	-0.97	-0.01	-0.82
Accounts Payable	0.56	0.64	0.72	-0.41	0.81	0.77	0.56	-0.26	-0.89		0.45	0.52	0.56	0.45	0.54	0.52	-0.01	0.41	0.94	-0.44	0.85	0.7	0.71	0.86	0.01	0.6
Cash	0.84	0.49	0.68	0.28	0.73	0.66	0.63	-0.82	-0.7	0.45		0.62	0.6	0.86	0.61	0.9	-0.38	0.42	0.53	-0.54	0.79	0.75	0.74	0.77	0.3	0.7
Non Current Assets Total	0.89	0.73	0.87	0.33	0.68	0.72	0.97	-0.11	-0.75	0.52	0.62		0.76	0.71	0.85	0.78	0.08	0.65	0.44	-0.04	0.78	0.74	0.83	0.8	0.36	0.98
Non Currrent Assets Other	0.75	0.74	0.8	0.21	0.44	0.66	0.64	-0.19	-0.76	0.56	0.6	0.76		0.51	0.64	0.72	-0.14	0.27	0.53	-0.08	0.68	0.81	0.81	0.71	0.23	0.78
Other Assets	0.81	0.52	0.74	0.2	0.77	0.65	0.76	-0.59	-0.65	0.45	0.86	0.71	0.51		0.67	0.81	-0.12	0.7	0.42	-0.51	0.77	0.58	0.71	0.77	0.3	0.73
Long Term Debt	0.88	0.86	0.91	0.35	0.75	0.76	0.86	-0.2	-0.76	0.54	0.61	0.85	0.64	0.67		0.82	0.31	0.74	0.47	0.07	0.74	0.76	0.88	0.77	0.03	0.86
Cash And Short Term Investments	0.97	0.78	0.86	0.45	0.79	0.85	0.78	-0.62	-0.81	0.52	0.9	0.78	0.72	0.81	0.82		-0.04	0.64	0.56	-0.24	0.82	0.87	0.9	0.83	0.09	0.84
Net Receivables	0.03	0.43	0.19	0.2	0.07	0.15	0.14	0.52	0.01	-0.01	-0.38	0.08	-0.14	-0.12	0.31	-0.04		0.51	-0.13	0.66	-0.14	-0.01	0.14	-0.07	-0.55	0.05
Common Stock Total Equity	0.69	0.72	0.72	0.28	0.72	0.74	0.73	-0.16	-0.55	0.41	0.42	0.65	0.27	0.7	0.74	0.64	0.51		0.31	-0.04	0.58	0.42	0.63	0.61	-0.22	0.62
Common Stock Shares Outstanding	0.55	0.58	0.66	-0.43	0.76	0.79	0.45	-0.41	-0.9	0.94	0.53	0.44	0.53	0.42	0.47	0.56	-0.13	0.31		-0.55	0.86	0.68	0.7	0.86	-0.09	0.53
Short Term Investments	-0.16	0.12	-0.14	0.53	-0.43	-0.28	-0.09	0.67	0.37	-0.44	-0.54	-0.04	-0.08	-0.51	0.07	-0.24	0.66	-0.04	-0.55		-0.53	-0.11	-0.15	-0.47	-0.23	-0.09
Non Current Liabilities Total	0.85	0.69	0.86	-0.08	0.91	0.88	0.8	-0.51	-0.96	0.85	0.79	0.78	0.68	0.77	0.74	0.82	-0.14	0.58	0.86	-0.53		0.8	0.87	1.0	0.16	0.83
Other Current Assets	0.88	0.81	0.86	0.28	0.74	0.8	0.73	-0.41	-0.86	0.7	0.75	0.74	0.81	0.58	0.76	0.87	-0.01	0.42	0.68	-0.11	0.8		0.93	0.81	0.18	0.85
Other Stockholder Equity	0.92	0.9	0.98	0.21	0.79	0.9	0.83	-0.33	-0.92	0.71	0.74	0.83	0.81	0.71	0.88	0.9	0.14	0.63	0.7	-0.15	0.87	0.93		0.89	0.07	0.9
Total Liab	0.86	0.74	0.89	-0.06	0.91	0.9	0.81	-0.46	-0.97	0.86	0.77	0.8	0.71	0.77	0.77	0.83	-0.07	0.61	0.86	-0.47	1.0	0.81	0.89		0.12	0.85
Deferred Long Term Liab	0.18	-0.25	0.06	0.07	0.09	-0.2	0.36	-0.08	-0.01	0.01	0.3	0.36	0.23	0.3	0.03	0.09	-0.55	-0.22	-0.09	-0.23	0.16	0.18	0.07	0.12		0.36
Property Plant And Equipment Gross	0.94	0.76	0.91	0.33	0.75	0.77	0.97	-0.21	-0.82	0.6	0.7	0.98	0.78	0.73	0.86	0.84	0.05	0.62	0.53	-0.09	0.83	0.85	0.9	0.85	0.36

Click cells to compare fundamentals

Syros Pharmaceuticals Account Relationship Matchups

Syros Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Other Current Liab	10.6M	9.4M	13.6M	15.9M	13.8M	10.7M
Total Current Liabilities	23.5M	28.6M	31.5M	30.8M	36.7M	22.2M
Total Stockholder Equity	79.2M	90.6M	85.2M	127.7M	16.7M	15.8M
Other Liab	22.6M	29.6M	3.0M	24.5M	28.1M	29.5M
Net Tangible Assets	79.2M	125.4M	106.1M	148.6M	170.9M	179.4M
Property Plant And Equipment Net	31.9M	29.6M	27.3M	24.7M	19.5M	16.6M
Net Debt	(15.5M)	(107.8M)	(27.1M)	(103.9M)	(77.5M)	(81.3M)
Retained Earnings	(293.0M)	(377.0M)	(463.6M)	(558.2M)	(722.8M)	(686.7M)
Accounts Payable	5.9M	3.6M	3.7M	6.4M	11.5M	12.1M
Cash	41.4M	174.0M	92.3M	167.5M	139.5M	93.7M
Non Current Assets Total	35.5M	34.7M	46.4M	33.1M	23.2M	21.7M
Non Currrent Assets Other	490K	2.0M	6.0M	5.3M	3.7M	2.6M
Other Assets	3.6M	20.5M	6.0M	8.4M	9.7M	5.4M
Cash And Short Term Investments	91.4M	174.0M	130.4M	202.3M	139.5M	119.8M
Common Stock Total Equity	26K	34K	43K	56K	20K	28.2K
Common Stock Shares Outstanding	4.0M	4.6M	6.3M	12.6M	28.3M	29.7M
Short Term Investments	39.8M	49.8M	50.0M	0.0	38.1M	34.8M
Liabilities And Stockholders Equity	150.0M	213.3M	182.9M	244.5M	168.2M	147.5M
Non Current Liabilities Total	47.3M	94.1M	66.2M	86.0M	114.8M	120.6M
Other Current Assets	2.6M	2.2M	3.2M	7.4M	5.5M	2.8M
Other Stockholder Equity	372.1M	467.5M	548.8M	685.8M	739.4M	377.3M
Total Liab	70.8M	122.7M	97.7M	116.8M	151.5M	159.1M
Property Plant And Equipment Gross	31.9M	29.6M	37.1M	37.2M	27.1M	19.9M
Total Current Assets	114.5M	178.6M	136.6M	211.4M	145.0M	125.8M
Accumulated Other Comprehensive Income	24K	0.0	(79K)	102K	117.3K	123.2K
Short Term Debt	1.3M	3.5M	4.0M	4.1M	11.3M	11.9M
Common Stock	34K	43K	56K	61K	20K	32.1K
Property Plant Equipment	31.9M	14.2M	27.3M	11.4M	13.1M	12.6M
Short Long Term Debt Total	25.9M	66.2M	65.2M	63.6M	62.1M	34.7M
Long Term Debt Total	22K	621K	39.6M	40.6M	46.7M	49.1M
Capital Surpluse	296.1M	372.1M	467.5M	685.8M	788.7M	828.2M
Current Deferred Revenue	5.7M	12.2M	10.2M	4.3M	5.0M	6.4M
Retained Earnings Total Equity	(217.5M)	(293.0M)	(377.0M)	(558.2M)	(502.4M)	(477.3M)
Capital Lease Obligations	25.9M	26.7M	24.9M	22.9M	20.9M	16.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC